Episode Details

Bristol Myers Squibb’s Q2 earnings beat expectations, lifting its stock as Eliquis—its blockbuster blood thinner with Pfizer—shows stronger-than-expected sales growth. But Morgan Stanley remains bearish, holding an “Underweight” rating and a $40 price target, citing looming patent expirations and delayed pipeline drugs like Milvexian and Cobenfy that could stall future growth. While the company shines now with solid dividends and near-term profits, investors are divided on whether its pipeline can sustain momentum beyond the patent cliff.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/9d48f0088ca9d6e3